Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lynch syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Lynch syndrome. Displaying page 1 of 1.
    EudraCT Number: 2014-000411-14 Sponsor Protocol Number: 6639 Start Date*: 2014-07-17
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological misma...
    Medical condition: Lynch Syndrome also known as HNPCC (non hereditary non polyposis colorectal cancer).
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10051981 Lynch syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001815-30 Sponsor Protocol Number: SGUL/SGH 001 Start Date*: 2006-06-05
    Sponsor Name:St George's, University of London (SGUL) [...]
    1. St George's, University of London (SGUL)
    2. Queen Mary and Westfield College, University of London (QMUL)
    Full Title: Prevention Of Endometrial Tumours (POET)
    Medical condition: Endometrial cancer/tumours in women with Hereditary Non-polyposis Colorectal Cancer (HNPCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051981 Lynch syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003548-35 Sponsor Protocol Number: MesaCAPP Start Date*: 2017-03-10
    Sponsor Name:Medical University of Vienna
    Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome
    Medical condition: Colorectal Cancer Prevention in Lynch syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10051981 Lynch syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003011-55 Sponsor Protocol Number: MesaCAPP Start Date*: 2020-07-23
    Sponsor Name:Karolinska Institute
    Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
    Medical condition: Lynch Syndrome, which is increasing the risk of developing colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051981 Lynch syndrome LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005584-33 Sponsor Protocol Number: KUN2009 Start Date*: 2010-02-09
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI
    Medical condition: In this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patient...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004364-11 Sponsor Protocol Number: 69HCL15_0321 Start Date*: 2016-03-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS
    Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005733-16 Sponsor Protocol Number: DNLI-H-0001 Start Date*: 2022-07-19
    Sponsor Name:Denali Therapeutics Inc.
    Full Title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in ...
    Medical condition: Frontotemporal Dementia (FTD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) PT (Trial now transitioned) CZ (Completed) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003880-61 Sponsor Protocol Number: 060-CL-305 Start Date*: 2005-02-08
    Sponsor Name:Yamanouchi Europe B.V.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE POTENTIAL EFFICACY, SAFETY AND TOLERABILITY OF DIFFERENT ORAL DOSES OF YM060 IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE ...
    Medical condition: diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    10023003
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-000461-23 Sponsor Protocol Number: CA209-627 Start Date*: 2017-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
    Medical condition: Advanced/Metastatic malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003159-12 Sponsor Protocol Number: J4B-MC-OKAA Start Date*: 2021-12-24
    Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
    Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002251-11 Sponsor Protocol Number: TPN-101-C9-201 Start Date*: 2021-12-06
    Sponsor Name:Transposon Therapeutics, Inc
    Full Title: A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia)
    Medical condition: Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 hexanucleotide repeat expansion
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002013-37 Sponsor Protocol Number: TRx-237-020 Start Date*: 2014-10-06
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia
    Medical condition: Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) BE (Completed) HR (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003289-18 Sponsor Protocol Number: 219369 Start Date*: 2023-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
    Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:19:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA